IN2014CN02850A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02850A
IN2014CN02850A IN2850CHN2014A IN2014CN02850A IN 2014CN02850 A IN2014CN02850 A IN 2014CN02850A IN 2850CHN2014 A IN2850CHN2014 A IN 2850CHN2014A IN 2014CN02850 A IN2014CN02850 A IN 2014CN02850A
Authority
IN
India
Prior art keywords
methylbenzenesulfonamide
indazol
reconstitution
pyrimidinyl
methylamino
Prior art date
Application number
Other languages
English (en)
Inventor
Augustus Campbell Gossett
Helen Richardson
Peter A Williams
Original Assignee
Glaxosmithkline Intellectual Property Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Ltd filed Critical Glaxosmithkline Intellectual Property Ltd
Publication of IN2014CN02850A publication Critical patent/IN2014CN02850A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2850CHN2014 2011-10-31 2012-10-16 IN2014CN02850A (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553454P 2011-10-31 2011-10-31
PCT/US2012/060361 WO2013066616A1 (en) 2011-10-31 2012-10-16 Pazopanib formulation

Publications (1)

Publication Number Publication Date
IN2014CN02850A true IN2014CN02850A (hu) 2015-07-03

Family

ID=48192602

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2850CHN2014 IN2014CN02850A (hu) 2011-10-31 2012-10-16

Country Status (12)

Country Link
US (3) US9278099B2 (hu)
EP (1) EP2773204A4 (hu)
JP (2) JP6200893B2 (hu)
KR (1) KR101993436B1 (hu)
CN (1) CN104254249B (hu)
AU (1) AU2012332952B2 (hu)
BR (1) BR112014010551A2 (hu)
CA (1) CA2852912A1 (hu)
HK (1) HK1201685A1 (hu)
IN (1) IN2014CN02850A (hu)
RU (1) RU2616500C2 (hu)
WO (1) WO2013066616A1 (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015145157A1 (en) * 2014-03-28 2015-10-01 Cipla Limited Pharmaceutical composition comprising pazopanib
EP3612184A4 (en) * 2017-04-17 2021-01-20 Yale University COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ACUTE LUNG INJURY
WO2019053500A1 (en) 2018-04-17 2019-03-21 Alvogen Malta Operations (Row) Ltd PHARMACEUTICAL COMPOSITION OF SOLID DOSAGE FORM CONTAINING PAZOPANIB AND PROCESS FOR PREPARING THE SAME
CN112236146A (zh) 2018-04-24 2021-01-15 盐野义制药株式会社 稳定性优良的固体制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH675537A5 (hu) 1988-03-25 1990-10-15 Ciba Geigy Ag
ES2054089T3 (es) 1988-11-10 1994-08-01 Ciba Geigy Ag Formulaciones orales liquidas.
SI1343782T1 (sl) * 2000-12-21 2009-10-31 Smithkline Beecham Corp Pirimidinamini kot modulatorji angiogeneze
CZ12993U1 (cs) * 2001-11-23 2003-02-10 Glaxo Group Limited Farmaceutický prostředek
RU2255730C1 (ru) * 2003-10-14 2005-07-10 Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") Стабильная фармацевтическая суспензия азитромицина и способ ее получения
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
ATE500831T1 (de) * 2005-11-29 2011-03-15 Glaxosmithkline Llc Krebsbehandlungsverfahren
DK1968594T3 (da) * 2005-11-29 2010-12-13 Glaxosmithkline Llc Behandling af okulære neovaskulære lidelser, såsom makulær degeneration, striae angioides og makulært ødem
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
BRPI0820198A2 (pt) * 2007-11-12 2019-09-24 Novartis Ag composições farmacêuticas
CL2008000374A1 (es) * 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
CN102065893A (zh) * 2008-04-15 2011-05-18 萨可德公司 Lfa-1拮抗剂向胃肠***的递送
WO2010037095A2 (en) * 2008-09-29 2010-04-01 Nometics Agents and methods for the treatment of cancer
US20100291025A1 (en) * 2009-04-13 2010-11-18 Auspex Pharmaceuticals, Inc. Indazole inhibitors of tyrosine kinase
EP2298321A1 (en) * 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
US8501811B2 (en) * 2010-06-17 2013-08-06 Washington University TASPASE1 inhibitors and their uses

Also Published As

Publication number Publication date
US10596263B2 (en) 2020-03-24
US20140255505A1 (en) 2014-09-11
BR112014010551A2 (pt) 2017-05-02
RU2014115289A (ru) 2015-12-10
RU2616500C2 (ru) 2017-04-17
CA2852912A1 (en) 2013-05-10
AU2012332952B2 (en) 2016-05-05
KR101993436B1 (ko) 2019-06-26
CN104254249A (zh) 2014-12-31
EP2773204A1 (en) 2014-09-10
HK1201685A1 (en) 2015-09-11
US20180360971A1 (en) 2018-12-20
JP2017197542A (ja) 2017-11-02
US10080802B2 (en) 2018-09-25
KR20140096082A (ko) 2014-08-04
US9278099B2 (en) 2016-03-08
AU2012332952A1 (en) 2014-05-15
JP6423484B2 (ja) 2018-11-14
WO2013066616A1 (en) 2013-05-10
JP6200893B2 (ja) 2017-09-20
CN104254249B (zh) 2017-02-15
EP2773204A4 (en) 2015-05-27
JP2014534215A (ja) 2014-12-18
US20160120988A1 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
PH12016501535A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
EA201291348A1 (ru) Активаторы растворимой гуанилатциклазы
BR112012031297A2 (pt) formulações de spray oral e métodos para administração de sildenafil
MX2013001677A (es) Formulaciones estables de linaclotida.
SG10201804817TA (en) Delayed release compositions of linaclotide
RS53898B1 (en) QUINAZOLINE-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS
SG11201502622VA (en) PYRROLO[3,2-<i>D</i>]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
MD20150050A2 (ro) Soluţii midriatice şi antiinflamatorii stabile fără conservanţi pentru injectare
GEP201706774B (en) Heterocyclyl compounds
MX357043B (es) Inhibidores selectivos de pi3k delta.
MX358172B (es) Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson.
MX2014006026A (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
MX348606B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2).
IL217052A0 (en) Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
NZ707160A (en) A stable aqueous composition comprising human insulin or an analogue or derivative thereof
NZ628072A (en) Crystalline pi3 kinase inhibitors
UA116875C2 (uk) Поліморфи arry-380 селективного інгібітору erbb2 і фармацевтичні композиції, що їх містять
MX2013010046A (es) Administracion parenteral de tapentadol.
IN2014CN02850A (hu)
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
MY186698A (en) Solid forms of ceftolozane
PH12016500322A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
MX2014013664A (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida.
TN2012000105A1 (en) Spirolactam derivatives and uses of same